Data Foundry

Drug recalls 2013

Errin — Class III drug recall D-689-2013

Terminated recall by Teva Pharmaceuticals USA, Inc., reported 2013-07-17, distributed nationwide. Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was de

Recall numberD-689-2013
Product typeDrug
ClassificationClass III
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmTeva Pharmaceuticals USA, Inc., Sellersville, PA, United States
Recall initiated2013-03-15
Classified2013-07-11
Reported by FDA2013-07-17
Terminated2014-01-15
DistributedNationwide (US)
Quantity154,536 cartons
Reason classeschemical contamination, specification failure
NDC00555-0344-58
Lot numbers12/14, 3/15, 33801773A, 33801774A, 33801775A, 33801776A, 33802427A, 33802428A, 33802429A, 33802430A, 33802925A, 33802926A, 33803383A, 33803384A, 33803385A, 33803387A, 33803685A, 6/15, 7/14, 8/14, 9/14

Product

Errin (norethindrone tablets, USP), 0.35 mg, 6 blister cards per carton, 28 tablets each, 28 day regimen, Rx Only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-0344-58

Reason for recall

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-689-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.